DIPHTHERIA TOXOID
Fallopian Tube Carcinosarcoma
Mayo ClinicvaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Fallopian Tube Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Mayo Clinic | Phase 2 | B |
Pembrolizumab Mayo Clinic | Phase 2 | B |
Inno-206 National Cancer Institute (NCI) | Phase 2 | B |
ADSORBED PURIFIED PERTUSSIS VACCINE Mayo Clinic | Phase 2 | CCC |
Hycamtin Mayo Clinic | Phase 2 | CCC |
View all 20 →
Same molecule, other indications
DIPHTHERIA TOXOID is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →